Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912534 · ClinicalTrials.gov registry record · Phase 2
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
A Phase 2 study, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT01912534: Completed Phase 2 study, sponsored by Carelon Research.
NCT01912534 is a Phase 2 study that has completed, run by Carelon Research. The registered enrollment target is 211 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01912534, a Phase 2 study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
Primary Outcome
Composite z-score which is the average of 9 change-scores of: serum NTproBNP, serum high-sensitivity cardiac troponin, left ventricular (LV) mass, left atrial (LA) volume, LV end diastolic volume, LV end systolic volume, maximal LV wall thickness, echo E' velocity, echo S' velocity
Interventions
- DRUG Placebo
- DRUG Valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-07 |
| Phase | Phase 2 |
What the finished NCT01912534 record still lists
NCT01912534 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01912534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01912534 about?
NCT01912534 is a clinical study titled "Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM". The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
What is the current status of trial NCT01912534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2014-03. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01912534?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG).
Who is sponsoring clinical trial NCT01912534?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01912534's enrollment target sits among peer trials
211 290th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia